Drug Profile
Research programme: antibacterial protein-based therapeutics - Phico Therapeutics
Alternative Names: PT2.0; PT3; PT3.33; PT4.0; SASP programme; SASPject™ PT3.1; SASPject™PT2.0; SASPject™PT4; SASPject™PT5Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Phico Therapeutics
- Class Peptides
- Mechanism of Action Bacterial DNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Escherichia coli infections; Klebsiella infections; Pseudomonal infections
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Escherichia-coli-infections in United Kingdom
- 28 Feb 2022 No recent reports of development identified for preclinical development in Klebsiella-infections in United Kingdom
- 28 Feb 2022 No recent reports of development identified for preclinical development in Pseudomonal-infections in United Kingdom (IV, Injection)